Simeon S, Jongkon N, Chotpatiwetchkul W, Gleeson M
J Comput Aided Mol Des. 2019; 33(8):745-757.
PMID: 31494804
DOI: 10.1007/s10822-019-00221-z.
Couly F, Harari M, Dubouilh-Benard C, Bailly L, Petit E, Diharce J
Molecules. 2018; 23(9).
PMID: 30158487
PMC: 6225322.
DOI: 10.3390/molecules23092181.
Hedou D, Godeau J, Loaec N, Meijer L, Fruit C, Besson T
Molecules. 2016; 21(5).
PMID: 27144552
PMC: 6273584.
DOI: 10.3390/molecules21050578.
Durieu E, Prina E, Leclercq O, Oumata N, Gaboriaud-Kolar N, Vougogiannopoulou K
Antimicrob Agents Chemother. 2016; 60(5):2822-33.
PMID: 26902771
PMC: 4862455.
DOI: 10.1128/AAC.00021-16.
Han Y, Zhao S, Gong Y, Hou G, Li X, Li L
Oncotarget. 2015; 7(2):1854-62.
PMID: 26636538
PMC: 4811502.
DOI: 10.18632/oncotarget.6443.
Homopharma: a new concept for exploring the molecular binding mechanisms and drug repurposing.
Chiu Y, Tseng J, Liu K, Lin C, Hsu K, Yang J
BMC Genomics. 2014; 15 Suppl 9:S8.
PMID: 25521038
PMC: 4290623.
DOI: 10.1186/1471-2164-15-S9-S8.
Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I.
Foucourt A, Hedou D, Dubouilh-Benard C, Desire L, Casagrande A, Leblond B
Molecules. 2014; 19(10):15546-71.
PMID: 25268714
PMC: 6270991.
DOI: 10.3390/molecules191015546.
Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.
Foucourt A, Hedou D, Dubouilh-Benard C, Girard A, Taverne T, Casagrande A
Molecules. 2014; 19(10):15411-39.
PMID: 25264830
PMC: 6271009.
DOI: 10.3390/molecules191015411.
The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.
Romano G
Scientifica (Cairo). 2014; 2013:317186.
PMID: 24381788
PMC: 3870877.
DOI: 10.1155/2013/317186.
Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases.
Paricharak S, Klenka T, Augustin M, Patel U, Bender A
J Cheminform. 2013; 5(1):49.
PMID: 24330772
PMC: 3900467.
DOI: 10.1186/1758-2946-5-49.
CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.
Delehouze C, Godl K, Loaec N, Bruyere C, Desban N, Oumata N
Oncogene. 2013; 33(50):5675-87.
PMID: 24317512
PMC: 4087096.
DOI: 10.1038/onc.2013.513.
Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.
Romano G
ISRN Oncol. 2013; 2013:305371.
PMID: 23840966
PMC: 3690251.
DOI: 10.1155/2013/305371.
Comparative amino acid decomposition analysis of potent type I p38α inhibitors.
Ebadi A, Razzaghi-Asl N, Khoshneviszadeh M, Miri R
Daru. 2013; 21(1):41.
PMID: 23714278
PMC: 3680208.
DOI: 10.1186/2008-2231-21-41.
KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms.
Chiu Y, Lin C, Huang J, Hsu K, Tseng J, You S
Nucleic Acids Res. 2012; 41(Database issue):D430-40.
PMID: 23193279
PMC: 3531076.
DOI: 10.1093/nar/gks1218.
Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations.
Songtawee N, Gleeson M, Choowongkomon K
J Mol Model. 2012; 19(2):497-509.
PMID: 22955422
DOI: 10.1007/s00894-012-1559-0.
Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads.
Oduor R, Ojo K, Williams G, Bertelli F, Mills J, Maes L
PLoS Negl Trop Dis. 2011; 5(4):e1017.
PMID: 21483717
PMC: 3071371.
DOI: 10.1371/journal.pntd.0001017.
Cross-reactivity virtual profiling of the human kinome by X-react(KIN): a chemical systems biology approach.
Brylinski M, Skolnick J
Mol Pharm. 2010; 7(6):2324-33.
PMID: 20958088
PMC: 2997910.
DOI: 10.1021/mp1002976.
Comprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening.
Brylinski M, Skolnick J
J Chem Inf Model. 2010; 50(10):1839-54.
PMID: 20853887
PMC: 2963673.
DOI: 10.1021/ci100235n.
Rationally designed PKA inhibitors for positron emission tomography: Synthesis and cerebral biodistribution of N-(2-(4-bromocinnamylamino)ethyl)-N-[11C]methyl-isoquinoline-5-sulfonamide.
Vasdev N, LaRonde F, Woodgett J, Garcia A, Rubie E, Meyer J
Bioorg Med Chem. 2008; 16(9):5277-84.
PMID: 18346896
PMC: 5328674.
DOI: 10.1016/j.bmc.2008.03.013.
